Mini Review
Published on 15 Sep 2023
Beyond liver cancer, more application scenarios for alpha-fetoprotein in clinical practice
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1231420
- 1,771 views
- 1 citation
Type at least 3 characters
1,765 articles
Articles
Original Research
Published on 14 Sep 2023
LTe2 induces cell apoptosis in multiple myeloma by suppressing AKT phosphorylation at Thr308 and Ser473
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1269670
- 1,387 views
Hypothesis and Theory
Published on 14 Sep 2023
Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1267532
- 1,882 views
- 1 citation
Original Research
Published on 13 Sep 2023
System analysis based on the lysosome-related genes identifies HPS4 as a novel therapy target for liver hepatocellular carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1221498
- 1,583 views
- 1 citation
Review
Published on 12 Sep 2023
Cellular senescence: a double-edged sword in cancer therapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1189015
- 10,450 views
- 20 citations
Review
Published on 08 Sep 2023
Single domain Camelid antibody fragments for molecular imaging and therapy of cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1257175
- 3,331 views
- 2 citations
Original Research
Published on 08 Sep 2023
Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1238883
- 2,688 views
- 2 citations
Original Research
Published on 07 Sep 2023
CAR requires Gadd45β to promote phenobarbital-induced mouse liver tumors in early stage
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1217847
- 1,610 views
- 2 citations
Original Research
Published on 06 Sep 2023
Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1207081
- 2,812 views
- 5 citations
Case Report
Published on 06 Sep 2023
Case Report: Cancer spectrum and genetic characteristics of a de novo germline POLD1 p.L606M variant-induced polyposis syndrome
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1222873
- 1,887 views
Original Research
Published on 06 Sep 2023
Development and validation of novel immune-inflammation-based clinical predictive nomograms in HER2-negative advanced gastric cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1185240
- 1,607 views
- 1 citation
Review
Published on 06 Sep 2023
Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1227657
- 4,387 views
- 4 citations
Original Research
Published on 01 Sep 2023
Cross-species evaluation of fibroblast activation protein alpha as potential imaging target for soft tissue sarcoma: a comparative immunohistochemical study in humans, dogs, and cats
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1210004
- 2,609 views
- 1 citation
Original Research
Published on 31 Aug 2023
GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1199432
- 2,953 views
- 8 citations
Original Research
Published on 31 Aug 2023
MiR-4270 acts as a tumor suppressor by directly targeting Bcl-xL in human osteosarcoma cells
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1220459
- 1,357 views
- 2 citations
Original Research
Published on 31 Aug 2023
Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1230382
- 2,651 views
- 1 citation